Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Event Clear all
Completed Not applicable Interventional

Meds@HOME App to Support Medication Safety

NCT05816590
View directory record Official record
Conditions
Medication Errors and Other Product Use Errors and Issues
Interventions
Med@HOME Mobile App
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Not applicable Interventional

Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

NCT00767689
View directory record Official record
Conditions
Hand and Foot Syndrome
Interventions
Vitamin B 6, placebo
Drug
Lead sponsor
Cook County Health
Government
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia

NCT01856010
View directory record Official record
Conditions
Dementia, Aggression, Agitation
Interventions
ECT treatment, Standard Care (Non-ECT group)
Other
Lead sponsor
Pine Rest Christian Mental Health Services
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety of Pediatric COVID-19 Vaccination

NCT05157191
View directory record Official record
Conditions
Pain, Injection Site Reaction, Adverse Drug Event
Interventions
Observational
Other
Lead sponsor
Duke University
Other
Eligibility
5 Years to 15 Years
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Role of Stress CMR in Predicting Adverse Clinical Events in Patients With Known or Suspected IHD

NCT01821924
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 100 Years
Enrollment
2,347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients

NCT07151820
View directory record Official record
Conditions
Leukemia, Chronic Myeloid
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 4 Interventional

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

NCT00050635
View directory record Official record
Conditions
Neoplasms, Diarrhea
Interventions
Sandostatin LAR Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Burbank, California • Concord, California • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

NCT05686980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Anaheim, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Risk of Acute Liver Injury in Users of Antimicrobials

NCT01434173
View directory record Official record
Conditions
Drug-Induced Liver Injury
Interventions
Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,299,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Many Locations, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated No phase listed Observational

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

NCT00504218
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 24 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer

NCT01153282
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 22, 2026, 8:30 AM EDT
Enrolling by invitation No phase listed Observational

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

NCT06211413
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Interventions
no intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

NCT00126425
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

NCT00616018
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
acetaminophen
Drug
Lead sponsor
Kennon Heard
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00492089
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Malignant Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineocytoma, Malignant Neoplasm, Meningeal Melanocytoma, Radiation Toxicity, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity
Interventions
bevacizumab, placebo, magnetic resonance imaging, quality-of-life assessment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Phase 3 Interventional

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
132
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

NCT05575037
View directory record Official record
Conditions
Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

NCT04895436
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
15
States / cities
La Jolla, California • Atlanta, Georgia • Des Moines, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging at Different Levels of Magnetic Intensity

NCT00001619
View directory record Official record
Conditions
Cardiovascular Disease, Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 8:30 AM EDT